Procter & Gamble Health's Stock Price Soars 6.88% on Strong Market Performance

Nov 05 2024 09:30 AM IST
share
Share Via
Procter & Gamble Health, a midcap pharmaceutical and drug company, saw a 6.88% increase in its stock price on November 5th, 2024. This rise is attributed to the company's strong performance in the market, with a 'Hold' rating from MarketsMojo. The stock has been on an upward trend, outperforming the sector and currently trading above its moving averages. It also offers a high dividend yield of 4.72%.

Procter & Gamble Health, a midcap pharmaceutical and drug company, has seen a 6.88% increase in its stock price on November 5th, 2024. This rise in stock price has been attributed to the company's strong performance in the market.

According to MarketsMOJO, a leading financial analysis and research firm, the stock of Procter & Gamble Health is currently rated as 'Hold'. This rating is based on the company's recent performance and market trends.

The stock of Procter & Gamble Health has been on an upward trend, hitting a new 52-week high of Rs. 5730.75 on the same day. It has also outperformed the sector by 7.18% and has been gaining for the last two days, with a return of 9.78% in that period. The stock opened with a gain of 4.9% today and reached an intraday high of Rs. 5730.75, showing high volatility with an intraday volatility of 68.38%.

Procter & Gamble Health is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in the market. Additionally, the company offers a high dividend yield of 4.72% at the current price.

In comparison to the Sensex performance, Procter & Gamble Health has shown a 1-day performance of 7.16% while the Sensex has shown a performance of -0.07%. Similarly, in the last month, Procter & Gamble Health has outperformed the Sensex with a performance of 6.49% compared to the Sensex's -3.62%.

Overall, Procter & Gamble Health has shown a strong performance in the market, with a positive trend and high dividend yield. Investors may want to keep an eye on this midcap company as it continues to make strides in the pharmaceutical and drug industry.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News